Spotlight on Hematology

Credits: 0.25 CME
The Next Steps in CAR T-Cell Therapy for the Treatment of Patients With Lymphoma
Julie Vose, MD, MBA
University of Nebraska Medical Center

The Next Steps in CAR T-Cell Therapy for the Treatment of Patients With Lymphoma

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credits
Released: August 31, 2018
Expires: August 31, 2019
20 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Provider

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Target Audience

The target audience for this activity is for community and academic medical oncologists, hematologists, advanced practitioners, and other clinicians who treat patients with lymphoma.

Learning Objectives

After completing this activity, participants should be better able to:

  • Review clinical trial data that led to approval of CAR T-cell–based therapies for the treatment of patients with lymphoma
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with lymphoma, including various combination strategies being examined
  • Develop strategies to mitigate adverse events often encountered with the use of CAR T-cell therapy, including cytokine release syndrome and neurotoxicity

Activity Description

Expert Insights is an interview involving 2 world renowned experts actively engaged in treatment of patients with lymphoma. This discussion features expert summary and interpretation of data presented during the 2018 Pan Pacific Lymphoma Conference in Hawaii, as well as provide guidance on the optimal use of current and emerging therapies.

Statement of Educational Need

CD19-targeted CAR T cells have emerged as a highly effective therapy in patients with NHL. However, multiple CAR T-cell technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with aggressive NHL need expert guidance to evaluate clinical data on CAR T-cell therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.

Faculty

Julie M. Vose, MD, MBA - Moderator
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Grants/Research Support: Acerta Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Kite Pharma, Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis, Seattle Genetics, Inc.

Consultant Fees, Honorarium: AbbVie Inc., Epizyme, Inc., Karyopharm Therapeutics, Legend Pharmaceuticals, Novartis, Roche, Sandoz, Vaniam Group LLC


Sattva S. Neelapu, MD
Professor
Deputy Department Chair ad interim
Director of Laboratory and Translational Research
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Grants/Research Support, Advisor: Acerta Pharma, Bristol-Myers Squibb Company, Cellectis, Gilead, Karus, Kite, A Gilead Company, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Poseida

Consultant, Advisor: Celgene Corporation, Kite, A Gilead Company, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis, Unum Therapeutics


Conflict of Interest Policy/Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

Educational grant support provided by Celgene Corporation and Kite, A Gilead Company.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

University of Nebraska Medical Center, Center for Continuing Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250

Bio Ascend
meetings@bioascend.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Hematology Presentations

0.50 CME
University of Nebraska Medical Center
Podium to Practice: Updates from Chicago Regarding Recent Advances in CAR T-cell Therapy for the Treatment of Hematologic Malignancies

Podium to Practice: Updates from Chicago Regarding Recent Advances in CAR T-cell Therapy for the Treatment of Hematologic Malignancies

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: July 17, 2019
Expires: July 17, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Provider

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who are interested in the use of CAR T-cell therapy for the treatment of patients with hematologic malignancies.

Learning Objectives

After completing this activity, participants should be better able to:

  • Review clinical trial data of current and emerging CAR T-cell therapies that are being investigated in patients with hematologic malignancies, including lymphoma, leukemia, and multiple myeloma
  • Discuss the potential for using CAR T-cell-based therapies in patients with other malignancies
  • Discuss common adverse events that are associated with CAR T-cell therapy, and develop strategies to mitigate such adverse events

Activity Description

Podium to Practice is a discussion among two renowned experts actively engaged in clinical trials and the management of patients with CAR T cells. This exchange features expert summary and interpretation of data presented during the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, and provides guidance on the optimal use of CAR T cells for patients with hematologic malignancies.

Statement of Educational Need

CAR T cells have emerged as a highly effective therapy in patients with hematologic malignancies and show promise in patients with solid tumors. However, multiple CAR T technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with these agents need expert guidance to evaluate clinical data of CAR T therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.

Faculty

Matthew Lunning, DO - Moderator
Associate Professor
Internal Medicine
Division of Oncology & Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Consulting Fees: AbbVie, Inc., Bayer, Celgene Corporation, DAVA, Gilead Sciences, Inc., Janssen, Juno Therapeutics, Kite Pharma, Novartis, OncLive, Portola, Seattle Genetics, Spectrum Pharmaceuticals, TG Therapeutics, Vaniam Group, Verastem
Grants/Research Support: Celgene Corporation, Curis, Janssen Scientific Affairs, LLC, Juno Therapeutics, MiRagen, TG Therapeutics


Reem Karmali, MD, MS
Assistant Professor
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois

Advisory Board: Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma
Grants/Research Support: Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma, Takeda Pharmaceutical Company Ltd
Speakers Bureau: Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma


Conflict of Interest Policy/Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

This program may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

Contact Information for Questions About the Activity

University of Nebraska Medical Center, Center for Continuing Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250

Bio Ascend
cme@bioascend.com

1.00 CME / CNE / CPE
Rush University Medical Center
Expert Perspectives in the Management of Chronic Lymphocytic Leukemia: Integrating Current and Emerging Agents/Regimens to Develop Evidence Based Clinical Management Strategies

Expert Perspectives in the Management of Chronic Lymphocytic Leukemia: Integrating Current and Emerging Agents/Regimens to Develop Evidence Based Clinical Management Strategies

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 2, 2019
Expires: July 1, 2020
1 hour to complete

Accredited by

Rush University Medical Center

Co-provided by

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Chronic Lymphocytic Leukemia.

Learning Objectives

After completing this program, participants should be able to:

1: Apply the latest data to risk stratify and optimize treatment plans for patients with CLL based on prognostic and predictive markers

2: Differentiate between first-line and relapsed/refractory treatment approaches for the treatment of CLL using the latest evidence-based guidelines

3: Explain the emerging clinical data and ongoing trials on novel agents and therapeutic strategies that have the potential to improve patient outcomes for patients with CLL

4: Summarize evidence-based management strategies that can be used to identify and treat acute and long-term complications associated with CLL treatment including: barriers to treatment, adherence, comorbidities, advanced age, etc.

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for CLL along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with CLL, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Jonathon B. Cohen, MD, MS (Course Director)
Department of Hematology and Medical Oncology
Emory University
Winship Cancer Institute
Atlanta, GA


Conflict of Interest Policy/Disclosure Statement

Jonathon B. Cohen, MD, MS, has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity.

Advisor: Janssen, Genentech
Research Funding: Genentech

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from AbbVie, Inc, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and TG Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Expert Perspectives on Improving Treatment of Patients with B-cell Non Hodgkin Lymphomas

Expert Perspectives on Improving Treatment of Patients with B-cell Non Hodgkin Lymphomas

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: November 9, 2018
Expires: November 8, 2019
60 minutes to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

Healthcare providers who are involved with the treatment of patients with B-cell lymphomas

Learning Objectives

After completing this program, participants should be able to:

  • Summarize current best-practice approaches for treatment of patients with different subtypes of indolent and aggressive B-cell non-Hodgkin lymphomas (NHLs)
  • Asses recent clinical advances and emerging treatment options for the management of B-cell NHLs, including next generation mAbs, BTK inhibitors, PI3K inhibitors, IMiDs, Bcl-2 inhibitors, and ongoing clinical trials
  • Evaluate patient, disease, and treatment-related considerations to optimize patient outcomes while providing the best standard of care for patients with B-cell NHLs

Activity Description

This activity provides healthcare providers with much needed professional education on treatment algorithms; recent clinical advances, emerging treatments, and clinical trials; as well as considerations to optimize patient outcomes while providing the best standard of care for patients with B-cell NHLs.

Faculty

Thomas E. Witzig, MD
Professor of Medicine Mayo Clinic College of Medicine
Co-PI, University of Iowa/Mayo Clinic Lymphoma SPORE
Deputy Director of Clinical Research, Mayo Clinic Cancer Center
Rochester, MN


Conflict of Interest Policy/Disclosure Statement

Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

It is the policy of the Rush University Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest (including but not limited to pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic) within the preceding 12 months.

The course directors, planners and faculty of this activity have the following relevant financial relationships to disclose.

Thomas E. Witzig, MD
Research Grant: Celgene, Novartis, Acerta - for research trial expenses, no personal money received
Consultant: Celgene (personally uncompensated)

Michaela Ryan, PhD
Nothing to disclose

Beth-Anne M. Christopher, MS, RN, CNL
Nothing to disclose

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing education unit(s) in Pharmacy. UAN: JA0000275-0000-18-130-H01-P.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Inc., Celgene Corp., Novartis, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., AbbVie, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions About the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME
University of Nebraska Medical Center
The Next Steps in CAR T-Cell Therapy for the Treatment of Patients With Lymphoma

The Next Steps in CAR T-Cell Therapy for the Treatment of Patients With Lymphoma

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credits
Released: August 31, 2018
Expires: August 31, 2019
20 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Provider

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Target Audience

The target audience for this activity is for community and academic medical oncologists, hematologists, advanced practitioners, and other clinicians who treat patients with lymphoma.

Learning Objectives

After completing this activity, participants should be better able to:

  • Review clinical trial data that led to approval of CAR T-cell–based therapies for the treatment of patients with lymphoma
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with lymphoma, including various combination strategies being examined
  • Develop strategies to mitigate adverse events often encountered with the use of CAR T-cell therapy, including cytokine release syndrome and neurotoxicity

Activity Description

Expert Insights is an interview involving 2 world renowned experts actively engaged in treatment of patients with lymphoma. This discussion features expert summary and interpretation of data presented during the 2018 Pan Pacific Lymphoma Conference in Hawaii, as well as provide guidance on the optimal use of current and emerging therapies.

Statement of Educational Need

CD19-targeted CAR T cells have emerged as a highly effective therapy in patients with NHL. However, multiple CAR T-cell technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with aggressive NHL need expert guidance to evaluate clinical data on CAR T-cell therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.

Faculty

Julie M. Vose, MD, MBA - Moderator
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Grants/Research Support: Acerta Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Kite Pharma, Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis, Seattle Genetics, Inc.

Consultant Fees, Honorarium: AbbVie Inc., Epizyme, Inc., Karyopharm Therapeutics, Legend Pharmaceuticals, Novartis, Roche, Sandoz, Vaniam Group LLC


Sattva S. Neelapu, MD
Professor
Deputy Department Chair ad interim
Director of Laboratory and Translational Research
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Grants/Research Support, Advisor: Acerta Pharma, Bristol-Myers Squibb Company, Cellectis, Gilead, Karus, Kite, A Gilead Company, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Poseida

Consultant, Advisor: Celgene Corporation, Kite, A Gilead Company, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis, Unum Therapeutics


Conflict of Interest Policy/Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

Educational grant support provided by Celgene Corporation and Kite, A Gilead Company.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

University of Nebraska Medical Center, Center for Continuing Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250

Bio Ascend
meetings@bioascend.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
University of Nebraska Medical Center
The Time is Now: Focusing on New and Emerging Therapies for Improving Patient Outcomes in AML

The Time is Now: Focusing on New and Emerging Therapies for Improving Patient Outcomes in AML

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: August 20, 2018
Expires: August 20, 2019
45 minutes to complete

Accredited By

University of Nebraska Medical Center, Center for Continuing Education

Provided By


This activity is co-provided by University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc.

Target Audience

This program is intended for hematologists, medical oncologists, health system pharmacists, oncology nurses, nurse practitioners, physician assistants, and other healthcare providers involved in the care of patients with AML.

Learning Objectives

Upon completion of this educational activity, participants should be better able to:

  • Describe the pathophysiology of AML and identify potential therapeutic targets
  • Summarize current clinical trial evidence regarding the efficacy and safety of new and emerging therapies for AML
  • Outline an approach to AML treatment selection that is tailored based upon individual patient characteristics

Activity Description

Despite recent advances in understanding of the pathophysiology of AML and a corresponding expansion of targeted treatment modalities, the care of individuals with the disease remains a significant challenge in current clinical practice. The following program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote accurate disease classification and risk assessment, and personalized treatment for patients with AML, including older individuals and those with relapsing or refractory disease.

Faculty

Jorge E. Cortes, MD
Jorge E. Cortes, MD
Jane and John Justin Distinguished Chair in Leukemia Research
Section Chief of AML & CML
Deputy Chairman
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas


Richard M. Stone, MD
Richard M. Stone, MD
Professor of Medicine
Harvard Medical School
Chief of Staff
Director, Adult Acute Leukemia Program
Dana-Farber Cancer Institute
Boston, Massachusetts


Conflict of Interest Policy/Disclosure Statement

The University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by The University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Jorge E. Cortes, MD, has no real or apparent conflicts of interest to report.

Richard M. Stone, MD
Consultant: Abbvie, Agios, Amgen, Argenix, Arog, Astellas, Celator, Celgene, Cornerstone, Fujifilm, Janssen, Jazz, Juno, Karyopharm, Merck, Novartis, Ono, Orsenix, Otsuka, Pfizer
Research: Agios, Arog, Novartis
Board Member: Actinium
Steering Committee: Celgene

Patima Tanapat, PhD, has no real or apparent conflicts of interest to report.

Accreditation Statement for Physicians

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of August 20, 2018 through August 20, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The University of Nebraska Medical Center, Center for Continuing Education, Integrity Continuing Education, Inc. and Pfizer do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about this activity, please contact the University of Nebraska Medical Center, Center for Continuing Education at (402) 559-4152 or via email at conted@unmc.edu.